4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina SpecialistsGlobeNewswireJune 30, 2026EMERYVILLE, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced a podium presentation at the 44th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) being held in Montreal, Canada, from July 15 - 18, 2026.
ASRS 2026Presentation Details:
Title:2-Year Follow Up: PRISM Phase 2b Clinical Trial EvaluatingInvestigational 4D-150, an Intravitreal Gene Therapy, in aBroad Neovascular AMD PopulationDate/Time:Saturday, July 18, 2026 (2:58 - 3:01 p.m. ET)Presenter:Carl Awh, MD, FASRS, Tennessee RetinaThe presentation will also be available on the 4DMT website: https://4dmoleculartherapeutics.com/pipeline/#posters-and-publications
About 4DMT
4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) with a single intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company's lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company's second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics(TM), 4DMT(TM), Therapeutic Vector Evolution(TM) and the 4DMT logo are trademarks of 4DMT.��
All of the Company's product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company's product candidates for the therapeutic uses for which they are being studied.â?¯Learn more at www.4DMT.com and follow us on LinkedIn.
Contacts:
Media:
Jenn Gordondna CommunicationsMedia@4DMT.com
Investors:
Julian PeiHead of Investor Relations and Strategic FinanceInvestor.Relations@4DMT.com
COMTEX_485209946/2010/2026-06-30T16:04:23
EMERYVILLE, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced a podium presentation at the 44th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) being held in Montreal, Canada, from July 15 - 18, 2026.
ASRS 2026Presentation Details:
Title:2-Year Follow Up: PRISM Phase 2b Clinical Trial EvaluatingInvestigational 4D-150, an Intravitreal Gene Therapy, in aBroad Neovascular AMD PopulationDate/Time:Saturday, July 18, 2026 (2:58 - 3:01 p.m. ET)Presenter:Carl Awh, MD, FASRS, Tennessee RetinaThe presentation will also be available on the 4DMT website: https://4dmoleculartherapeutics.com/pipeline/#posters-and-publications
About 4DMT
4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) with a single intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company's lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company's second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics(TM), 4DMT(TM), Therapeutic Vector Evolution(TM) and the 4DMT logo are trademarks of 4DMT.��
All of the Company's product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company's product candidates for the therapeutic uses for which they are being studied.â?¯Learn more at www.4DMT.com and follow us on LinkedIn.
Contacts:
Media:
Jenn Gordondna CommunicationsMedia@4DMT.com
Investors:
Julian PeiHead of Investor Relations and Strategic FinanceInvestor.Relations@4DMT.com
COMTEX_485209946/2010/2026-06-30T16:04:23
2.99% $0.31
